ICBs, currently used or in development for NSCLC treatment, include the anti-PD-1 antibodies nivolumab (human IgG4) and pembrolizumab (humanized IgG4), along with the anti-PD-L1 antibodies atezolizumab (human IgG1, with the Fc domain engineered to prevent antibody-directed cell cytotoxicity), durvalumab (human IgG1 engineered), and avelumab (human IgG1 showing preclinical antibody-directed cell cytotoxicity activity) [74]. Here, CD274 is linked to non-small cell lung carcinoma.